guiding decision-making by both patients and providers while we await the results of the trial comparing three cycles of EI with the use of a histology-tailored regimen in selected histotypes.
introduction Approximately half of advanced melanoma patients will develop melanoma brain metastases (MBMs) in their treatment course [1] . The median overall survival (OS) for patients with MBMs has been reported to be 4-5 months in the literature [1, 2] .
Novel targeted and immunotherapeutic agents have revolutionized systemic management of melanoma. A number of prospective clinical trials have demonstrated these agents either alone or in combination can prolong progression-free survival (PFS) and OS [3, 4] . Several studies have assessed the impact of these agents in patients with MBMs in the prospective setting [5] [6] [7] . Our group as well as other institutions have reported outcomes of patients managed with vemurafenib and ipilimumab for systemic management with stereotactic radiation for the management of MBMs [8] [9] [10] . These studies have shown the safety and feasibility of such an approach; however, comparative outcomes assessing the impact of combined modality management of MBMs remain limited.
Our group recently reported the first series of patients treated with stereotactic radiation for the management of MBMs within 6 months of the receipt of the anti-PD-1 therapy, nivolumab [11] . OS and distant MBM control appeared improved over historical controls without significant toxicity. Given these findings, we undertook an analysis at our institution comparing the intracranial control rate in patients treated with stereotactic radiosurgery (SRS) for intact MBMs within 3 month of the receipt of anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors(i), BRAFi, or conventional chemotherapy.
methods
This study was approved by the University of South Florida Institutional Review Board. Data were analyzed retrospectively from our institutional database of patients treated with SRS for MBMs. A total of 310 patients were treated for MBMs over 429 SRS treatment sessions at our institution between January 2007 and August 2015. Patients were included if they were diagnosed with MBMs and treated with single-fraction SRS within 3 months of treatment with anti-PD-1 therapy (nivolumab or pembrolizumab), anti-CTLA-4 therapy (ipilimumab), combined BRAF/MEKi (dabrafenib and trametinib), BRAFi alone (vemurafenib), or conventional chemotherapy. A cutpoint of 3 months was used to more accurately assess the role of SRS with various systemic agents and to limit the effect of other treatments aside from the tested regimen affecting clinical outcomes. The assigned regimen was the last course of systemic treatment to avoid the effects of multiple systemic agents influencing clinical end points. Patients who underwent surgical resection of MBMs before SRS were excluded.
systemic treatment regimens and SRS technique
Nivolumab or pembrolizumab comprised the anti-PD-1 therapy regimen. Seven patients (33%) were treated with pembrolizumab and 14 patients (67%) were treated with nivolumab. Patients treated with nivolumab received 3 mg/kg q 2 weeks or 2 mg/kg pembrolizumab q 3 weeks. The anti-CTLA-4 therapy, ipilimumab, was administered over 4 infusions every 3 weeks dosed to 3 mg/kg. All patients receiving the BRAF/MEKi regimen or BRAFi alone harbored the V600E mutation. The BRAF/MEKi regimen consisted of daily doses of dabrafenib 150 mg twice a day (b.i.d.) and trametinib 2 mg daily administration. Patients receiving BRAFi alone received vemurafenib 960 mg b.i.d. In patients receiving concurrent BRAF/MEKi or BRAFi alone with SRS, patients were instructed to hold the drug 2-3 days before and after SRS. The majority of patients treated with conventional chemotherapy received carboplatin and paclitaxel (n ¼ 8; 40%). The remaining conventional chemotherapy cohort consisted of three Annals of Oncology original articles patients treated with dacarbazine (15%), three patients temozolomide (15%), two patients carboplatin and paclitaxel followed by temozolomide (10%), two patients cisplatin, dacarbazine, and vinblastine (10%), one patient carboplatin and dacarbazine (5%), and one patient cisplatin, vinblastine, and temozolomide (5%).
Treatments were delivered with the BrainLab Novalis Classic linear accelerator (LINAC) with 6 MV photons. These methods have been previously described [11] . All MBMs were treated with SRS in a single session.
follow-up
Patients in this study were followed with clinical examinations and MRI imaging at 2-3 month intervals. There were no differences in clinical or radiographic follow-up intervals between treatment groups. Images were assessed alongside two neuroradiologists at our institution (JAA and DGS). The primary end point of this study was distant MBM control. Distant MBM control was defined as freedom from development of new MBM or leptomeningeal disease outside of the irradiated field. Local MBM failure was defined as at least a 20% radiographic increase in the size of the previously irradiated area in accordance with RECIST criteria [12] . RECIST criteria have been used previously by our group [10, 11, 13] and was determined to be more established than RANO criteria [14] at the time of analysis. Secondary end points in this study included local MBM control, systemic PFS (sPFS), as well as OS from the date of SRS and the date of intracranial diagnosis and neurotoxicity.
statistical analysis
Statistical analyses were carried out using JMP 11 (SAS Institute Inc., Cary, NC). The local and distant MBM control rates, as well as OS, were calculated from the date of MBM diagnosis or radiation treatment to the date of progression or death using the Kaplan-Meier (KM) method, with the log-rank test used to test differences. To test differences between cohorts, the KruskalWallis, Pearson's v 2 , and Fisher's exact tests were used when appropriate. The Cox proportional hazard model analyses were carried out using univariate analysis (UVA) and multivariate analysis (MVA). Variables that showed significant effects on UVA (P < 0.1) were included in the MVA. Table S1 , available at Annals of Oncology online. The median follow-up of patients after MBMs diagnosis was 7.4 months (range: 0.1-46.2 months).
The majority of SRS sessions were treated concurrently or after systemic treatment (n ¼ 72; 61%) and the majority of lesions were treated with 24 Gy (n ¼ 128; 41%). The median gross tumor volume (GTV) was 0.14 cm 3 (range: 0.008-9.48 cm 3 ).
patient and lesion characteristics among groups
Patient and lesion characteristics among the five systemic treatment groups are displayed in Table 1 . Overall, the five groups were well balanced in terms of single or multiple metastases treated per patient (P ¼ 0.46), gender (P ¼ 0.85), age (P ¼ 0.27), diagnosis-specific graded prognostic assessment (P ¼ 0.51), use of steroids at the time of SRS (P ¼ 0.25), number of systemic organs affected by metastases (P ¼ 0.11), time from diagnosis of distant metastatic disease to time of SRS (P ¼ 0.40), and GTV (P ¼ 0.26). Differences were noted in the median SRS dose used per lesion among groups (P ¼ 0.005). Thirty-eight percent and 20% of patients were BRAF mutated in the anti-PD-1 and anti-CTLA-4 cohorts, respectively, while all patients treated with BRAFi had mutant tumor (P ¼ 0.0001). Owing to the era of diagnosis, BRAF mutation status was largely unknown for patients treated with conventional chemotherapy. In addition, there was a difference between groups in administration of previous systemic treatments (P ¼ 0.001).
distant and local MBM control KM distant MBM control rates at 6 and 12 months across all treatment sessions were 36% and 18%. Significant differences were noted among the groups in distant MBM control rates following SRS, P ¼ 0.008 ( Figure 1 ). Six-and 12-month distant MBM control rates were 61%/38% (anti-PD-1 therapy), 26%/ 21% (anti-CTLA-4 therapy), 53%/20% (BRAF/MEKi), 30%/8% (BRAFi), and 15%/5% (conventional chemotherapy) following SRS. Distant MBM control UVA and MVA is detailed in KM local MBM control rates at 6 and 12 months were 89% and 83%, respectively. There were no significant differences among the groups in local MBM control rates, P ¼ 0.25. Dose (P ¼ 0.63), prior systemic treatment (P ¼ 0.57), and number of lesions treated per patient (P ¼ 0.42) were not predictive of local MBM failure, supplementary Table S2 , available at Annals of Oncology online.
systemic progression-free survival
The median sPFS from the date of SRS was 3.4 months (range: 0.47-45.9 months). Actuarial sPFS rates are displayed in supplementary Figure S1 , available at Annals of Oncology online. Sixand 12-month sPFS rates following SRS were 41%/41% (anti-PD-1 therapy), 36%/27% (anti-CTLA-4 therapy), 58%/39% (BRAF/MEKi), 29%/12% (BRAFi), and 20%/5% (chemotherapy) (P ¼ 0.04). UVA and MVA analysis of sPFS from the date of SRS is displayed in supplementary Table S3, available 
OS from SRS and cranial metastases diagnosis
The median OS for all patients in the study was 8.9 months (range: 0.47-48 months) from the date of SRS and 10.5 months SRS, stereotactic radiosurgery; KPS, Karnofsky performance status; DS-GPA, diagnosis-specific graded prognostic assessment; I, inhibitor; GTV, gross tumor volume.
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(0.5-48.2 months) from the date of cranial metastases diagnosis. Actuarial OS rates by treatment group from the date of SRS are displayed in Figure 2 . Six-and 12-month OS rates following SRS were 76%/48% (anti-PD-1 therapy), 68%/41% (anti-CTLA-4 therapy), 83%/65% (BRAF/MEKi), 52%/24% (BRAFi), and 60%/ 10% (chemotherapy) (P ¼ 0.01). Similar differences were noted in OS from the date of cranial metastases diagnosis with 6-and 12-month OS rates of 81%/66% (anti-PD-1 therapy), 84%/50% (anti-CTLA-4), 83%/75% (BRAF/MEKi), 71%/29% (BRAFi), 70%/15% (chemotherapy) (P ¼ 0.004). In those patients that died (n ¼ 73; 76%), imaging at last follow-up before death was assessed. The percentage of patients demonstrating progression in the brain alone, systemic alone, or both brain and systemic progression in the anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEKi, BRAFi, and chemotherapy cohorts was 16%/33%/ 50%, 19%/19%/63%, 70%/0%/30%, 47%/20%/33%, 25%/15%/ 60%, P ¼ 0.10, respectively. UVA and MVA analysis for OS from SRS is displayed in supplementary Table S4, available original articles Annals of Oncology selected systemic treatment regimen. Secondly, although distant MBM control differed, local MBM control among treatment groups was similar. Thirdly, OS from the date of SRS differed based on the selected treatment regimen. Lastly, systemic treatment with SRS was well tolerated without significant neurotoxicity, which would be expected with SRS alone. Conventional chemotherapy has failed to improve outcomes in patients with MBMs [15, 16] . There have been substantial advancements in the field of systemic melanoma management utilizing targeted and immunologic agents. A phase II trial of patients with asymptomatic and symptomatic MBMs treated with ipilimumab monotherapy demonstrated a 24% and 10% response rate in the brain with a median survival of 7 and 3 months, respectively [6] . Several retrospective series have assessed the combined management of MBMs with ipilimumab and SRS [8, 9] . These studies have demonstrated the feasibility of combined modality management. Clinical trials with anti-PD-1 therapies in patients with metastatic melanoma have demonstrated objective systemic responses in 25%-45% of patients [3, [17] [18] [19] . A recent study revealed over half of MBMs stain positive for PD-L1 by immunohistochemistry accompanied by lymphocytic infiltrates, which supports the potential for anti-PD-1 therapies in MBM patients [20] . Our group recently published the first series of patients treated with SRS and nivolumab for MBMs [11] . We found the two modalities could be safely combined with improved OS and distant MBM control noted over historical controls.
In this study, we compare distant MBM control rates with SRS and several systemic regimens. Previous studies have varied the time interval between radiation and systemic regimens with a variety of reported end points without direct comparison to other systemic treatments [8, 9, 21, 22] . To understand the difference in systemic regimens on distant and local MBM control as well as OS, we undertook an analysis of all melanoma patients treated with single-session SRS for intact, non-postoperative MBMs at our institution. We find the highest distant MBM control to be among patients treated with anti-PD-1 therapy. We report a distant MBM control rate of 21% at 12 months with SRS and ipilimumab, which appears comparable to the results of Kiess et al. [8] . Interestingly, only patients treated with ipilimumab or anti-PD-1 therapies displayed long-term distant MBM control following SRS in our analysis.
Patients treated more recently particularly those in the anti-PD-1 cohort were more likely to undergo prior systemic treatments. These patients may have presented with more advanced refractory disease; although, prior treatment agents may have also positively improved outcomes for patients treated with anti-PD-1 therapy. However, prior systemic treatment (Y/N) was not found to influence distant MBM control, local MBM control, sPFS, or OS in the present analysis. Patients treated with anti-PD-1 therapy, anti-CTLA-4 therapy, and BRAF/MEKi were treated with lower doses of SRS compared with BRAFi and conventional chemotherapy. This was due to a shift in the center's practice towards lower SRS dosing for melanoma metastases. There is the potential that slightly lower dosing may allow immune cells to remain viable positively influencing outcomes. In addition, lower SRS doses may preserve intact tumor-associated vasculature to mediate effective trafficking of immune cells from the periphery to the tumor site [23] .
The overall local MBM control rate in our study appears similar to previous series assessing management of MBMs treated with SRS alone. Results for local MBM control following SRS in 250 MBMs alone were reported to be 89% and 84% at 6 and 12 months [24] . This is almost identical to our local MBM control rate of 89% and 83% at 6 and 12 months. We would expect ablative SRS doses to produce adequate local control regardless of systemic management and in our study, local MBM control did not differ significantly based on treatment regimen. We found patients treated with BFAF/MEKi, anti-PD-1 therapy, and anti-CTLA-4 therapy each had improved OS over patients treated with conventional chemotherapy on MVA from the date of SRS. This is comparable to multiple, single institution retrospective series, which have demonstrated improved OS over historical controls with SRS and targeted and immunologic agents [8, 11, 13] .
There are several limitations to the present study. The primary limitation of the current analysis is its retrospective nature with end points and time intervals between drug delivery and SRS, which were not pre-defined to assess the study population. The assigned regimen was the last course of systemic treatment, which may introduce a bias potentially selecting for a poorer prognosis cohort. However, this was done to avoid the effect of multiple systemic agents influencing clinical end points and to more clearly evaluate differences between treatment groups.
Assessing distant MBM control as the primary end point over 119 SRS treatment sessions in the current analysis reveals an improvement with anti-PD-1 therapy and BRAF/MEKi regimens over conventional chemotherapy on MVA. These results warrant prospective evaluation of the potential synergistic effect that may take place between immunologic and targeted agents with SRS to improve outcomes in patients with MBMs. 
